Vancouver, Canada, September 5, 2023 - The International Society for Cell & Gene Therapy (ISCT) today officially announces the appointment of Dr. Edwin M. Horwitz, MD, PhD, as the new Editor-in-Chief of Cytotherapy, the official journal of ISCT. This new strategic position has been created to invest in and accelerate the growth and reach of the journal worldwide and to further Cytotherapy’s mission to become the premier cell and gene therapy translation journal.
Dr. Horwitz is an accomplished researcher, physician, and professor with a remarkable career spanning over 30 years in cell therapy. He holds the esteemed position of Marcus Professor of Cellular Therapy and is Professor of Pediatrics at Emory University School of Medicine. He also serves as the Co-Director of the Marcus Center for Pediatric Advanced Cellular Therapies, the Director of Transplantation Biology and Therapeutics in the Aflac Cancer & Blood Disorders Center and as an Attending Physician at Children's Healthcare of Atlanta. Dr. Horwitz brings notable editorial expertise to this new role with previous experience as the Associate Editor of Cytotherapy (2007-2016) and Associate Editor of Biology of Blood and Marrow Transplantation (2005-2017).
As Editor-in-Chief, Dr. Horwitz will play a pivotal role in shaping the journal's strategic direction, upholding the highest standards of peer-reviewed content and fostering collaboration within the scientific community. Dr. Horwitz's extensive engagement with ISCT over the past 24 years, during which he has held significant leadership roles such as ISCT President (2010-2012), Cytotherapy Associate Editor (2007-2016), and founding chairman of the MSC Committee, uniquely positions him to further the vision and mission of the journal and elevate Cytotherapy's reputation as a premier platform for disseminating groundbreaking research globally.
Speaking on the appointment, Edwin M. Horwitz, MD, PhD, stated, “I am delighted to assume the position of Cytotherapy Editor-in-Chief and continue my work with ISCT. Having been intimately involved with the Society throughout my career, I am excited to now have the opportunity to play a pivotal role in shaping the future success of its journal.”
He further shared his vision for the Journal’s growth, saying, “Cytotherapy is an outstanding journal but has yet to reach its full potential. To ensure growth, we must remain responsive to the changing landscape of cell and gene therapy (CGT). In the coming years, I will work closely with our editorial board and leadership to ensure that Cytotherapy continues to advance as the leading translational journal and the home of cutting-edge CGT research.”
Congratulating Dr. Horwitz on his appointment, Bruce Levine, PhD, Chair of the ISCT Publications Committee, stated, “Dr. Horwitz has displayed an unwavering commitment to ISCT for many years. His deep understanding of not only the cell and gene landscape but also the vision and mission of Cytotherapy is a significant asset. ISCT is confident that Dr. Horwitz’s dedication and expertise will bring about transformative changes and will make a profound impact on the continued success of Cytotherapy.”
Commenting on the significance of Dr. Horwitz's appointment, Jacques Galipeau, MD, ISCT President, stated, “Under Dr. Horwitz's leadership and in collaboration with the journal's editorial board, Cytotherapy will continue to thrive as a premier translation publication, attracting leading researchers, clinicians, and scholars from around the globe.”
About Cytotherapy
Cytotherapy is the official peer-reviewed journal of the International Society for Cell & Gene Therapy (ISCT). Established in 1999, the journal holds a five-year impact factor of 5.0. It publishes novel and innovative results from high-quality scientific and clinical studies related to cell, extracellular vesicles (EV) and gene translation in the field of cell and gene therapy.
Specific areas of interest include, but are not limited to:
- Development and characterization of novel gene therapies and cell and EV-based therapeutics
- Design of novel therapeutic approaches employing cell/EV/gene products.
- Mode of action of cell/EV/gene therapies in relevant cell-based and pre-clinical models.
- Identification of novel biomarkers that predict the potency of cell/EV/gene therapies and stratify patients based on response rates.
For more information about Cytotherapy, please visit https://www.isct-cytotherapy.org/ or @Cytotherapy.
About the International Society for Cell & Gene Therapy
Established in 1992, the International Society for Cell & Gene Therapy (ISCT) is a global society of clinicians, regulators, researchers, technologists, and industry partners with a shared vision to translate cell and gene therapy into safe and effective treatments to improve lives worldwide.
ISCT is the global leader focused on pre-clinical and translational aspects of developing cell and gene-based therapeutics, thereby advancing scientific research into innovative treatments for patients. ISCT offers a unique collaborative environment that addresses three critical areas of translation: Academia, Regulatory, and Commercialization. Through solid relationships with global regulatory agencies, academic institutions, and industry partners, ISCT drives the advancement of research into a standard of care.
Comprising over 3,000 cell and gene therapy experts across five geographic regions and with representation from over 60 countries, ISCT members are part of a global community of peers, thought leaders, and organizations invested in cell and gene therapy translation. For more information about the society, key initiatives, and upcoming meetings, please visit https://isctglobal.org or @ISCTglobal.
#Pressrelease